Natural killer (NK) cells are a promising tool in the fight against cancer. Engineering them with chimeric antigen receptors (CARs) further bolsters their specific anti-tumor activity.

This webinar describes how a new platform for high-throughput proteomics was used to identify multiple proteins associated with ovarian cancer. A 22-protein model was derived that discriminates ovarian cancer cases from benign controls with high accuracy.

This exclusive Ask Me Anything session delves into the cutting-edge advancements and international policy changes driving sustainability in the laboratory.

Liquid biopsies and the advent of blood-based diagnostics have emerged in recent years as promising alternatives and complements to tissue-based genomic and proteomic assays. Biodesix, a global leader in molecular diagnostics and assay design/development, leverages cutting-edge technology, including droplet digital PCR (ddPCR), to advance translational and clinical oncology research and to assist biopharma companies in delivering new, targeted, life-saving therapies to patients.

This presentation provides a comprehensive exploration of new blood-based diagnostics, including the development of a microsatellite instability (MSI) test on the ddPCR platform and the dynamic monitoring capabilities of ddPCR using circulating tumor DNA (ctDNA).

Transmembrane proteins (TPs) in their full-length and biologically active form presents challenges in purification primarily due to their innate complex structures. To overcome the challenges of expressing TPs, the FLAG technology from Acrobio addresses their protein expression knowledge to provide highly bioactive, stabilized, native full-length multi-pass transmembrane target antigens for the development of immune-related targeted therapeutics.

In this webinar, we will guide you through the essential steps of the CAR T workflow while emphasizing the critical role of in-process control and quality control.